Studies that evaluated systemic pharmacokinetics and plasma‐free VEGF levels following intravitreal injections for patients with AMD showed that all three anti‐VEGF agents are rapidly detected in the systemic circulation (Avery et al., 2014; Zehetner et al., 2015). Here, VEGFA is linked to age-related macular degeneration.